{"id":"detemir-insulin-aspart-insulin-metformin","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Hypoglycemia"},{"rate":"2–5","effect":"Weight gain"},{"rate":"1–5","effect":"Injection site reactions"},{"rate":"10–30","effect":"Gastrointestinal disturbance (metformin)"},{"rate":"<0.1","effect":"Lactic acidosis (metformin, rare)"}]},"_chembl":{"chemblId":"CHEMBL1201496","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Detemir is a basal insulin analog that provides steady, long-acting glucose control by binding to insulin receptors. Aspart is a rapid-acting insulin that covers mealtime glucose spikes. Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity via AMPK activation. Together, they address multiple pathways of hyperglycemia in type 2 diabetes.","oneSentence":"This combination therapy uses two insulin types (long-acting detemir and rapid-acting aspart) plus metformin to lower blood glucose by increasing insulin signaling and reducing hepatic glucose production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:23.962Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Type 1 diabetes mellitus (insulin component)"}]},"trialDetails":[{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT04222348","phase":"PHASE3","title":"MeDiGes Study: Metformine Use in Gestational Diabetes","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2016-10-26","conditions":"Diabetes, Gestational, Perinatal Disorder, Puerperal Disorder","enrollment":200},{"nctId":"NCT01966978","phase":"PHASE4","title":"The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-11","conditions":"Diabetes Mellitus, Type 2, Diabetes","enrollment":157},{"nctId":"NCT01850615","phase":"PHASE3","title":"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":323},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT01486966","phase":"PHASE4","title":"Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2011-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT01068652","phase":"PHASE4","title":"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":403},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00657943","phase":"PHASE4","title":"The Copenhagen Insulin and Metformin Therapy Trial","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2008-04","conditions":"Type 2 Diabetes, Atherosclerosis, Arteriosclerosis","enrollment":415},{"nctId":"NCT00942318","phase":"PHASE4","title":"Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":52},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT01022658","phase":"NA","title":"INSUlin Regimens and VASCular Functions","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-01","conditions":"Type 2 Diabetes","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Detemir insulin, Aspart insulin, Metformin","genericName":"Detemir insulin, Aspart insulin, Metformin","companyName":"University Hospital, Toulouse","companyId":"university-hospital-toulouse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy uses two insulin types (long-acting detemir and rapid-acting aspart) plus metformin to lower blood glucose by increasing insulin signaling and reducing hepatic glucose production. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus (insulin component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}